Overview of Ovugel

Property	Description
Active ingredient	Isoconazole nitrate
Form	Ovule, Intravaginal Gel, or Topical Cream/Solution
Pharmacological class	Azole antifungal agent
General purpose	Combating localized fungal and mixed infections
Origin	Synthetic (Imidazole derivative)

Ovugel: Identity and Pharmacological Classification

Ovugel is a pharmaceutical product containing the active ingredient, Isoconazole nitrate, a synthetic medicine used to manage infections caused by pathogenic fungi. This compound is categorized as an azole antifungal agent, belonging to the imidazole derivative family.

The drug entity, Isoconazole, is manufactured through chemical synthesis, distinguishing it from naturally derived antifungal sources. Isoconazole shows clinical effectiveness against common yeasts and molds. Its primary purpose is to halt the colonization and growth of various pathogens responsible for superficial and mucosal fungal infections, such as those occurring in vulvovaginal fungal infections, where a targeted action is essential.

Composition, Delivery, and Broad Action

Isoconazole is typically employed as a single-ingredient product, optimized for localized delivery via a topical or intravaginal route of administration. While the name Ovugel often refers to preparations intended for internal use, such as an ovule (vaginal tablet) or an intravaginal gel, the active substance is also available in cream and solution forms for external use. These specialized forms often utilize a lipid-based vehicle to ensure prolonged contact and sustained release of the medicine at the infection site.

A key attribute of Isoconazole is its broad spectrum of activity. It is effective against a wide range of fungi and yeasts, but it also possesses an inhibitory effect against certain Gram-positive bacteria that frequently co-exist with fungal pathogens. This dual activity ensures the formulation provides a more comprehensive approach to localized treatment, helping to address mixed infections and supporting the restoration of the microbial balance in the affected area.

What side effects are possible with Ovugel?

Possible Side Effects and Safety Information

Ovugel (Triptorelin Acetate Gel) is officially designated as an OTC Animal Drug for use in swine and is Not for Use in Humans, a foundational safety constraint governing its risk profile.

The regulatory documentation from government authorities focuses on safety warnings for human handlers and specific constraints for the target animal (sows).

Adverse Reactions and Systemic Concerns

The label for the target species (weaned sows) reports no known adverse reactions during clinical studies. However, its use is contraindicated in sows exhibiting obvious reproductive tract abnormalities.

For human handlers, the active ingredient, Triptorelin, a GnRH analogue, necessitates specific precautions concerning the following systems:

Ocular System: The product can cause eye irritation upon accidental contact.
Reproductive System: Accidental exposure may affect reproductive cycles in women.
Immune System: A serious adverse risk is the possibility of hypersensitivity or allergic reactions in individuals with a known sensitivity to GnRH analogues or any excipients.

Population and Duration Constraints

Safety statements identify specific populations that must adhere to restrictions. Pregnant women should not handle the product, as the effects of accidental exposure are unknown. Furthermore, the product must be kept out of reach of children. Within the target species, the efficacy and safety have not been established in gilts (young female swine), and the safety of treatment in subsequent reproductive cycles for treated sows has not been demonstrated.

Overdose and Emergency Response

The regulatory documentation for Ovugel is strictly based on its classification as an OTC Animal Drug, establishing an overdose profile defined by the mandatory safety warning, "Not for Use in Humans." This classification dictates the official information provided regarding over-administration and required emergency actions.

Documented Manifestations and Scope

The official labeling does not include descriptions of specific human clinical signs, symptoms, or physiological findings related to overdose or accidental human exposure. The limited safety data available concerning over-administration is derived exclusively from studies in the product’s target population: the weaned sow. In these regulatory safety studies, the administration of up to three times the recommended dose showed no documented adverse effects on reproductive performance or the health of the offspring.

Emergency Actions and Seeking Help

All official regulatory guidance on seeking help centers on accidental human exposure due to the product’s non-human designation. The product carries the regulatory mandate to be kept "Keep Out of Reach of Children". In the event of any accidental human contact or exposure, the explicit emergency response required is to consult the Material Safety Data Sheet (MSDS) for detailed occupational safety information. It is also officially noted in the regulatory profile that no specific antidote is known or documented for Triptorelin acetate gel over-administration, meaning any medical care would be symptomatic and supportive.

Therapeutic Uses of Ovugel

The primary use and therapeutic domain of Ovugel is in the veterinary field, rather than for human use. This product is classified as an OTC Animal Drug containing triptorelin acetate gel. The use for this product relates to facilitating reproductive timing, specifically the synchronization of time of insemination in weaned sows to facilitate a single fixed-time artificial insemination. The product plays a role in supporting agricultural operations by addressing the timing of the reproductive cycle, rather than providing human symptom relief. The product label states: “Not for Use in Humans.” This safety notice is essential for understanding Ovugel's intended use.

Misalignment with Human Symptomatic Domains

Ovugel is not relevant for easing symptoms related to physical discomfort, supporting functional stability, or managing human conditions presenting with acute episodes. The clinical scenario for which it is commonly used involves the controlled administration to livestock to achieve a biological event.

Quick Fact: Not for Human Use
Quick Fact: Ovugel is an OTC Animal Drug and is not approved for human symptomatic use.

Regulatory References

DailyMed label information on OVUGEL

Eligibility and Restrictions for Use

Who can and cannot use Ovugel?

The population eligibility for Ovugel (Triptorelin Acetate Gel) is strictly defined by its classification as an Over-the-Counter (OTC) Animal Drug used solely in veterinary practice.

Contraindications and Eligibility

Classification	Population/Group
Absolute Contraindication	Humans (The product label explicitly states: "Not for Use in Humans")
Approved Population	Weaned Sows for synchronization of time of insemination

Use Restrictions and Limitations

Eligibility is limited to the target species and is subject to specific physical conditions:

Not Approved: The medicine is not approved for use in gilts (nulliparous sows) as safety and effectiveness have not been evaluated in this population.
Not Recommended: Use is not recommended in sows during pregnancy and/or lactation, or in subsequent reproductive cycles.
Condition-Based Non-Eligibility: Ovugel must not be used in animals with obvious reproductive tract abnormalities, infertility, or general health disorders.

Its regulatory profile establishes an absolute species-based restriction, prohibiting use across all human age groups and conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ovugel (triptorelin acetate gel) is an officially documented Over-The-Counter (OTC) Animal Drug intended exclusively for use in swine to synchronize the time of artificial insemination. Regulatory documentation explicitly includes a safety notice stating, “Not for Use in Humans,” which is the primary context for evaluating its interaction profile.

The official regulatory records defining the product’s use, such as those published by the U.S. National Library of Medicine and the European Medicines Agency, state a formal absence of documented interactions with other medicinal products, food, or supplements.

Official Interaction Profile Summary

Interaction Domain	Status in Official Regulatory Documents
Drug–Drug Interactions	None documented.
Metabolic Interactions (e.g., CYP Enzymes)	None documented.
Timing-Based Separation Rules	None required for co-administered substances.
Food, Alcohol, or Supplements	None documented.

Regulatory documentation formally addresses the interaction profile by stating that “None known. No data available.” This means that the official labeling does not include specific requirements for timing separation, restrictions on co-administration, or warnings regarding pharmacokinetic or pharmacodynamic interactions with other substances. The profile is characterized by a lack of recorded interaction data, precluding the classification of contraindicated combinations or exposure-modifying effects.

Mechanism of Action

Targeted Inhibition of Fungal Sterol Production

The mechanism of action begins with the active ingredient, Isoconazole nitrate, binding to and inhibiting the critical fungal enzyme lanosterol 14alpha-demethylase (CYP51). This action specifically interrupts the ergosterol biosynthesis pathway, preventing the conversion of lanosterol into ergosterol . This mechanism engages the core biochemical processes responsible for fungal survival by targeting a key metabolic step.

Fungal Cell Membrane Destabilization and Lysis

The resulting depletion of ergosterol (essential for membrane structure) combined with the simultaneous accumulation of toxic intermediate sterols leads to the structural compromise of the fungal cell membrane. This profound failure in membrane integrity and function causes the leakage of cellular contents, resulting in both a fungistatic (growth-inhibiting) and, ultimately, a fungicidal (cell-killing) effect, thereby resulting in the reduction and destruction of the fungal population.

Secondary Antimicrobial Effect

Beyond its primary antifungal scope, the mechanism includes an auxiliary inhibitory effect against certain Gram-positive bacteria. This secondary action controls co-existing microbial proliferation, resulting in a broad local antimicrobial action.

Dosage and Administration Information

How to Use Ovugel — Official Administration Guidelines

Ovugel (dinoprost tromethamine) is administered as a single, fixed-time, intravaginal dose strictly following the established protocol.

Administration Scope

Feature	Official Instruction
Route of Administration	Intravaginal.
Dosing Schedule	A single 2 mL dose.
Administration Time	Approximately 96 hours after weaning of the sow.
Age-Group Rule	Approved for use only in weaned sows (multiparous).
Special Procedural Condition	Must be followed by artificial insemination at 22 ± 2 hours after Ovugel administration.

Procedural Requirements

Before administration, the product must be removed from refrigeration and allowed to warm at room temperature for a minimum of 10 minutes, and then administered within one hour of warming. The official procedure requires the use of a multi-dose applicator set to deliver 2 mL and a new protective sheath for each sow treated.

Official Step Sequence:

Warm the Ovugel bottle to room temperature for at least 10 minutes.
Attach the infusion tube to the applicator and place a new protective sheath over the tube.
Gently insert the covered infusion tube into the vagina at a slight upper angle until near the cervix, then withdraw the tube about 1/2 inch (1-3 cm).
Compress the applicator handle to discharge the single 2 mL dose.
Conduct artificial insemination 22 ± 2 hours following the administration of Ovugel.

These instructions define the standardized, time-critical administration and follow-up protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ovugel

Evidence for Synchronization of Ovulation in Sows

Research has explored the use of Ovugel (triptorelin acetate gel) within programs designed to allow a single, fixed-time artificial insemination (FTAI) in weaned sows. The evidence base is primarily composed of Randomized Controlled Trials (RCTs) and observational field trials conducted in commercial settings. Research was conducted to evaluate protocols for timed ovulation and was observed in settings comparing the FTAI approach to standard methods that rely on identifying when the animal is naturally ready for breeding.

Primary Outcomes Examined in Clinical Trials

The evidence base focused on measuring ovulation precision, exploring the short-term physiological changes in the reproductive cycle. Additionally, the studies examined the overall success of the reproductive event, measuring the farrowing rate (the number of females that successfully farrowed) and litter characteristics (such as total litter size). These outcomes contribute to understanding the longer-term functional health following the synchronized event.

Long-Term Studies and Follow-up

Long-term effects are not fully established beyond the first reproductive cycle. The research contributes to understanding short-term changes and functional metrics measured during the immediate study period, but the follow-up durations were limited in terms of tracking the consistency of reproductive outcomes in subsequent cycles. The evidence provides limited information for long-term outcomes or durability of response.

Evidence in Specific Sows Subgroups

The available data primarily reflect use in multiparous weaned sows—females that have previously given birth. Research examined whether outcomes varied across subgroups, sometimes defined by factors like the size of ovarian follicles at the time of treatment. Data for certain groups remain insufficient, particularly for nulliparous sows (gilts). Research has not established the necessary evidence to support the use of the product in this younger population.

What is Still Uncertain About Ovugel Research

The research highlights areas where evidence is limited or where outcomes can vary. Studies describe that the product's function appears to be highly sensitive to the correct timing of administration and the physiological status of the animal. Furthermore, findings were mixed regarding the consistency of reproductive results when the product was used in various commercial settings and different management practices. The research provides context but does not offer predictions regarding whether an individual animal will respond similarly across all operational conditions.

Key Studies & References OVUGEL (triptorelin acetate gel) product label - Synchronization of time of insemination in weaned sows

Frequently Asked Questions (FAQ)

Common questions about Ovugel (FAQ)

Q: Is Ovugel the generic or the brand name for this type of medication?

Ovugel is typically used as a brand name for different pharmaceutical products. Specifically, it is the official brand name for the veterinary drug (Triptorelin acetate) used in swine. The human antifungal medication (Isoconazole nitrate), which is also sometimes referred to as Ovugel, is commonly marketed under various other international brand names.

Q: How long can the effects of one application of Ovugel be expected to last?

Studies on the veterinary product (used for reproductive synchronization) indicate that the intended physiological effects are timed to occur within 40 to 48 hours following administration. This duration relates to the critical timing needed for the follow-up procedure defined in the official guidelines.

Q: Is it normal to feel a temporary tingling, warming, or cooling sensation upon applying Ovugel?

According to patient information for the human antifungal formulation (Isoconazole), it is possible to experience common application site reactions. These reactions may include mild stinging, redness, or itching in the treated area.

Q: What types of activities should be avoided immediately after applying Ovugel (e.g., swimming, sun exposure)?

Regulatory information for the human antifungal formulation indicates that avoiding vaginal intercourse during the course of treatment is advised. The official labeling may also include cautions regarding the simultaneous use of tampons, douches, or spermicides.

Q: What should a patient do if they notice the Ovugel changing color or consistency in the tube?

The product has strict storage requirements, including mandatory refrigeration for the veterinary version. If you observe any unexpected change in the medicine's appearance, color, or consistency, it may indicate the product is compromised. In such cases, official guidance recommends that the product be discarded according to safety disposal requirements.

Q: Is the medication Ovugel known by any other name internationally?

Yes. The active ingredient in the human antifungal formulation, Isoconazole nitrate, is marketed internationally under several other brand names. These include names such as Gyno-Travogen, Icaden, and Abimono.

Q: Are there official warnings about the risk of flammability associated with using Ovugel or materials that come into contact with it?

Safety information for the active ingredients indicates that the product should be kept away from heat, sparks, or open flames during handling. This measure is a standard precaution consistent with general chemical safety practices.

Q: What information is provided in the patient leaflet regarding potential overdose or overuse of Ovugel?

Information for the human antifungal product states that if more than the directed dose is used or the product is swallowed, contact with a healthcare professional is recommended.

Q: What is the process for reporting a possible side effect after using Ovugel?

Official regulatory information describes a process for reporting possible side effects or adverse events. This typically involves contacting the national competent authority (such as the FDA or EMA) or submitting a report directly to the marketing authorization holder.

Q: What are the signs of a possible allergic reaction to the ingredients in Ovugel?

Regulatory documents warn that the active ingredients can pose a risk of hypersensitivity to human handlers. Signs of a severe allergic reaction can include a sudden onset of swelling in the face, eyes, lips, or tongue, or experiencing difficulty in breathing.

Q: Are there any preservatives or inactive ingredients in Ovugel that commonly cause reactions?

Yes. The official veterinary labeling states that individuals with a known hypersensitivity to the active substance or any of the inactive ingredients (excipients), which may include parabens, must avoid contact with the product. This reflects a strict regulatory constraint on handler eligibility.

Q: Why is Ovugel applied topically instead of being taken orally?

The medication is formulated for localized delivery to ensure the active ingredient acts directly at the required site of administration. This approach is used to achieve targeted action, such as an antifungal effect in the human form or a specific reproductive effect in the veterinary form, rather than relying on systemic absorption.

Q: How quickly does Ovugel typically begin to work after the first use?

Studies indicate that for the veterinary product, the key physiological effect of ovulation synchronization is typically achieved within 40 to 48 hours after administration, leading to the required follow-up procedure.

Q: What is the recommended timeframe for expecting the full benefit of Ovugel treatment?

Research studies focused primarily on short-term physiological changes and immediate outcomes within the first treatment cycle. Official regulatory data indicates that the long-term effects or durability of response in subsequent reproductive cycles are not fully established.

Q: Are there any pre-existing medical conditions that prohibit the use of Ovugel?

For the veterinary product, official labeling states that use is contraindicated in animals that have reproductive tract abnormalities, infertility, or general health disorders that could compromise the success of the treatment.

Q: Are the research findings for Ovugel publicly available or summarized in official sources?

Yes. Official governmental bodies, such as the European Medicines Agency (EMA) and other relevant regulatory agencies, publish public release summaries and evaluation reports on the clinical trials and data that supported the product’s authorization.

Q: Is Ovugel designed to be used for a set period of time or for long-term management?

The veterinary protocol requires the use of the product as a single application. Furthermore, regulatory evidence is limited to the first reproductive cycle, and the safety of treatment in subsequent cycles has not been demonstrated.

Q: Does the efficacy of Ovugel change if it is applied too thinly or too thickly?

The veterinary drug is designed for consistent application. It is delivered using a specialized multi-dose applicator that releases a fixed 2 mL dose. This method is intended to ensure consistency in the volume and technique of application.

How should Ovugel be stored and disposed of?

Storage and Disposal Requirements for OvuGel

OvuGel (triptorelin acetate gel), a veterinary medicine, must be stored under controlled conditions to maintain stability.

Mandatory Storage and Stability

The product must be kept at refrigerator temperature, specifically between 36°F and 46°F (2°C and 8°C). Any exposure to warmer temperatures is restricted to a brief period, such as during shipping. The container stability is limited: after the bottle stopper is first punctured, the unused portion must be discarded after 28 days. The stopper may be punctured a maximum of three times within this period.

Handling and Protection

Before administration, the gel must be allowed to warm to room temperature for a minimum of 10 minutes and must be used within one hour of warming. The product must be stored Keep Out of Reach of Children.

Disposal

Official regulatory instructions prohibit disposal of unused or expired OvuGel through wastewater or household waste. Disposal must utilize established take-back schemes or national collection systems for veterinary medicinal products.

Ovugel